2017 MIPS Quality Outcome Measures

View all quality measures →

ID Name Type High Priority
329 Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis Outcome Yes
330 Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days Outcome Yes
384 Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery Outcome Yes
385 Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery Outcome Yes
458 All-cause Hospital Readmission Outcome No
354 Anastomotic Leak Intervention Outcome Yes
191 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery Outcome Yes
192 Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures Outcome Yes
303 Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery Outcome Yes
304 Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery Outcome Yes
389 Cataract Surgery: Difference Between Planned and Final Refraction Outcome Yes
388 Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vitrectomy) Outcome Yes
378 Children Who Have Dental Decay or Cavities Outcome Yes
409 Clinical Outcome Post Endovascular Stroke Treatment Outcome Yes
165 Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate Outcome Yes
167 Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure Outcome Yes
164 Coronary Artery Bypass Graft (CABG): Prolonged Intubation Outcome Yes
166 Coronary Artery Bypass Graft (CABG): Stroke Outcome Yes
168 Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration Outcome Yes
411 Depression Remission at Six Months Outcome Yes
370 Depression Remission at Twelve Months Outcome Yes
222 Functional Status Change for Patients with Elbow, Wrist or Hand Impairments Outcome Yes
219 Functional Status Change for Patients with Foot or Ankle Impairments Outcome Yes
223 Functional Status Change for Patients with General Orthopaedic Impairments Outcome Yes
218 Functional Status Change for Patients with Hip Impairments Outcome Yes
217 Functional Status Change for Patients with Knee Impairments Outcome Yes
220 Functional Status Change for Patients with Lumbar Impairments Outcome Yes
221 Functional Status Change for Patients with Shoulder Impairments Outcome Yes
338 HIV Viral Load Suppression Outcome Yes
392 HRS-12: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation Outcome Yes
348 HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate Outcome Yes
393 HRS-9: Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision Outcome Yes
395 Lung Cancer Reporting (Biopsy/Cytology Specimens) Outcome Yes
396 Lung Cancer Reporting (Resection Specimens) Outcome Yes
335 Maternity Care: Elective Delivery or Early Induction Without Medical Indication at >= 37 and < 39 Weeks (Overuse) Outcome Yes
397 Melanoma Reporting Outcome Yes
446 Operative Mortality Stratified by the Five STS-EACTS Mortality Categories Outcome Yes
398 Optimal Asthma Control Outcome Yes
342 Pain Brought Under Control Within 48 Hours Outcome Yes
424 Perioperative Temperature Management Outcome Yes
141 Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care Outcome Yes
457 Proportion Admitted to Hospice for less than 3 days Outcome Yes
455 Proportion Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life Outcome Yes
432 Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair Outcome Yes
433 Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair Outcome Yes
434 Proportion of Patients Sustaining a Ureter Injury at the Time of any Pelvic Organ Prolapse Repair Outcome Yes
454 Proportion of Patients who Died from Cancer with more than One Emergency Department Visit in the Last 30 Days of Life Outcome Yes
410 Psoriasis: Clinical Response to Oral Systemic or Biologic Medications Outcome Yes
435 Quality of Life Assessment For Patients With Primary Headache Disorders Outcome Yes
344 Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2) Outcome Yes
260 Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2) Outcome Yes
347 Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) Who Die While in Hospital Outcome Yes
259 Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post Operative Day #2) Outcome Yes
417 Rate of Open Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) Where Patients Are Discharged Alive Outcome Yes
258 Rate of Open Repair of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7) Outcome Yes
345 Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Artery Stenting (CAS) Outcome Yes
346 Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Endarterectomy (CEA) Outcome Yes
437 Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure Outcome Yes
445 Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG) Outcome Yes
343 Screening Colonoscopy Adenoma Detection Rate Outcome Yes
357 Surgical Site Infection (SSI) Outcome Yes
356 Unplanned Hospital Readmission within 30 Days of Principal Procedure Outcome Yes
355 Unplanned Reoperation within the 30 Day Postoperative Period Outcome Yes
420 Varicose Vein Treatment with Saphenous Ablation: Outcome Survey Outcome No

Email Alerts

Stay informed with Able Health email alerts

Be the first to know about key PQRS and MACRA information, deadlines, and expert analysis